Search

Displaying results 9741 - 9750 of 10000 in total
  1. Drug

    Mongersen

    go.drugbank.com/drugs/DB15019
    Investigational

    Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

  2. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    It is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market … Mercurochrome is a trade name of merbromin commonly used as a topical first-aid antiseptic agent.

    Products: MERBROMINA MARCO VITI
  3. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  4. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range. … Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.

  5. Drug

    Tiazofurine

    go.drugbank.com/drugs/DB13243
    Experimental

    Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].

    Synonyms: 2-(β-D-ribofuranosyl)-4-thiazolecarboxamide, 2-β-D-ribofuranosyl-4-thiazolecarboxamide
  6. Drug

    OPB-111077

    go.drugbank.com/drugs/DB16630
    Investigational

    OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.

  7. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.

  8. Drug

    Col-Treg

    go.drugbank.com/drugs/DB18451
    Experimental

    Col-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]

    Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagen
  9. Drug

    RCT1100

    go.drugbank.com/drugs/DB18830
    Investigational

    RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]

  10. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).